Histamine and Skin Barrier: Are Histamine Antagonists Useful for the Prevention or Treatment of Atopic Dermatitis?
Abstract
:1. Atopic Dermatitis (AD) and the Skin Barrier
2. Histamine Overview
3. Histamine and the Skin Barrier
4. Conclusions
Acknowledgments
Author Contributions
Conflicts of Interest
References
- Bieber, T. Atopic dermatitis. N. Engl. J. Med. 2008, 358, 1483–1494. [Google Scholar] [CrossRef] [PubMed]
- Elias, P.M.; Wakefield, J.S. Mechanisms of abnormal lamellar body secretion and the dysfunctional skin barrier in patients with atopic dermatitis. J. Allergy Clin. Immunol. 2014, 134, 781–791. [Google Scholar] [CrossRef] [PubMed]
- De Benedetto, A.; Kubo, A.; Beck, L.A. Skin barrier disruption: A requirement for allergen sensitization? J. Investig. Dermatol. 2012, 132, 949–963. [Google Scholar]
- Van Smeden, J.; Janssens, M.; Kaye, E.C.; Caspers, P.J.; Lavrijsen, A.P.; Vreeken, R.J.; Bouwstra, J.A. The importance of free fatty acid chain length for the skin barrier function in atopic eczema patients. Exp. Dermatol. 2014, 23, 45–52. [Google Scholar] [CrossRef] [PubMed]
- Kezic, S.; Novak, N.; Jakasa, I.; Jungersted, J.M.; Simon, M.; Brandner, J.M.; Middelkamp-Hup, M.A.; Weidinger, S. Skin barrier in atopic dermatitis. Front. Biosci. (Landmark Ed.) 2014, 19, 542–556. [Google Scholar] [CrossRef]
- Brandner, J.M.Z.-K.M.; Yoshida, T.; Moll, I.; Beck, L.A.; De Benedetto, A. Epidermal tight junctions in health and disease. Tissue Barriers 2015, 3. [Google Scholar] [CrossRef]
- De Benedetto, A.; Rafaels, N.M.; McGirt, L.Y.; Ivanov, A.I.; Georas, S.N.; Cheadle, C.; Berger, A.E.; Zhang, K.; Vidyasagar, S.; Yoshida, T.; et al. Tight junction defects in patients with atopic dermatitis. J. Allergy Clin. Immunol. 2011, 127, 773–786. [Google Scholar] [CrossRef] [PubMed]
- Esaki, H.; Ewald, D.A.; Ungar, B.; Rozenblit, M.; Zheng, X.; Xu, H.; Estrada, Y.D.; Peng, X.; Mitsui, H.; Litman, T.; et al. Identification of novel immune and barrier genes in atopic dermatitis by means of laser capture microdissection. J. Allergy Clin. Immunol. 2015, 135, 153–163. [Google Scholar] [CrossRef] [PubMed]
- Batista, D.I.; Perez, L.; Orfali, R.L.; Zaniboni, M.C.; Samorano, L.P.; Pereira, N.V.; Sotto, M.N.; Ishizaki, A.S.; Oliveira, L.M.; Sato, M.N.; et al. Profile of skin barrier proteins (filaggrin, claudins 1 and 4) and Th1/Th2/Th17 cytokines in adults with atopic dermatitis. J. Eur. Acad. Dermatol. Venereol. 2014. [Google Scholar] [CrossRef]
- Silverberg, J.I. Healthcare utilization, patient costs, and access to care in us adults with eczema: A population-based study. JAMA Dermatol. 2015. [Google Scholar] [CrossRef]
- Eichenfield, L.F.; Tom, W.L.; Berger, T.G.; Krol, A.; Paller, A.S.; Schwarzenberger, K.; Bergman, J.N.; Chamlin, S.L.; Cohen, D.E.; Cooper, K.D.; et al. Guidelines of care for the management of atopic dermatitis: Section 2. Management and treatment of atopic dermatitis with topical therapies. J. Am. Acad. Dermatol. 2014, 71, 116–132. [Google Scholar] [CrossRef] [PubMed]
- Sidbury, R.; Davis, D.M.; Cohen, D.E.; Cordoro, K.M.; Berger, T.G.; Bergman, J.N.; Chamlin, S.L.; Cooper, K.D.; Feldman, S.R.; Hanifin, J.M.; et al. Guidelines of care for the management of atopic dermatitis: Section 3. Management and treatment with phototherapy and systemic agents. J. Am. Acad. Dermatol. 2014, 71, 327–349. [Google Scholar] [CrossRef] [PubMed]
- Bieber, T.; Straeter, B. Off-label prescriptions for atopic dermatitis in Europe. Allergy 2015, 70, 6–11. [Google Scholar] [CrossRef] [PubMed]
- Schmitt, J.; Schakel, K.; Schmitt, N.; Meurer, M. Systemic treatment of severe atopic eczema: A systematic review. Acta Derm. Venereol. 2007, 87, 100–111. [Google Scholar] [CrossRef] [PubMed]
- Beck, L.A.; Thaci, D.; Hamilton, J.D.; Graham, N.M.; Bieber, T.; Rocklin, R.; Ming, J.E.; Ren, H.; Kao, R.; Simpson, E.; et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N. Engl. J. Med. 2014, 371, 130–139. [Google Scholar] [CrossRef] [PubMed]
- Simpson, E.L.; Chalmers, J.R.; Hanifin, J.M.; Thomas, K.S.; Cork, M.J.; McLean, W.H.; Brown, S.J.; Chen, Z.; Chen, Y.; Williams, H.C. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J. Allergy Clin. Immunol. 2014, 134, 818–823. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Horimukai, K.; Morita, K.; Narita, M.; Kondo, M.; Kitazawa, H.; Nozaki, M.; Shigematsu, Y.; Yoshida, K.; Niizeki, H.; Motomura, K.; et al. Application of moisturizer to neonates prevents development of atopic dermatitis. J. Allergy Clin. Immunol. 2014, 134, 824–830. [Google Scholar] [CrossRef] [PubMed]
- Sampson, H.A.; Jolie, P.L. Increased plasma histamine concentrations after food challenges in children with atopic dermatitis. N. Engl. J. Med. 1984, 311, 372–376. [Google Scholar] [CrossRef] [PubMed]
- Van Zuuren, E.J.; Apfelbacher, C.J.; Fedorowicz, Z.; Jupiter, A.; Matterne, U.; Weisshaar, E. No high level evidence to support the use of oral H1 antihistamines as monotherapy for eczema: A summary of a Cochrane systematic review. Syst. Rev. 2014, 3, 25. [Google Scholar] [CrossRef] [PubMed]
- Nguyen, T.; Shapiro, D.A.; George, S.R.; Setola, V.; Lee, D.K.; Cheng, R.; Rauser, L.; Lee, S.P.; Lynch, K.R.; Roth, B.L.; et al. Discovery of a novel member of the histamine receptor family. Mol. Pharmacol. 2001, 59, 427–433. [Google Scholar] [PubMed]
- Drake, L.A.; Fallon, J.D.; Sober, A. Relief of pruritus in patients with atopic dermatitis after treatment with topical doxepin cream. The Doxepin Study Group. J. Am. Acad. Dermatol. 1994, 31, 613–616. [Google Scholar] [CrossRef] [PubMed]
- Berberian, B.J.; Breneman, D.L.; Drake, L.A.; Gratton, D.; Raimir, S.S.; Phillips, S.; Sulica, V.I.; Bernstein, J.E. The addition of topical doxepin to corticosteroid therapy: An improved treatment regimen for atopic dermatitis. Int. J. Dermatol. 1999, 38, 145–148. [Google Scholar] [CrossRef] [PubMed]
- Kabashima, K. New concept of the pathogenesis of atopic dermatitis: Interplay among the barrier, allergy, and pruritus as a trinity. J. Dermatol. Sci. 2013, 70, 3–11. [Google Scholar] [CrossRef] [PubMed]
- Dale, H.H.; Laidlaw, P.P. The physiological action of beta-iminazolylethylamine. J. Physiol. 1910, 41, 318–344. [Google Scholar] [CrossRef] [PubMed]
- Bovet, D. Introduction to antihistamine agents and antergan derivative. Ann. N. Y. Acad. Sci. 1950, 50, 1089–1126. [Google Scholar] [CrossRef] [PubMed]
- Leurs, R.; Vischer, H.F.; Wijtmans, M.; de Esch, I.J. En route to new blockbuster anti-histamines: Surveying the offspring of the expanding histamine receptor family. Trends Pharmacol. Sci. 2011, 32, 250–257. [Google Scholar] [CrossRef] [PubMed]
- Kubo, Y.; Nakano, K. Regulation of histamine synthesis in mouse CD4+ and CD8+ T lymphocytes. Inflamm. Res. 1999, 48, 149–153. [Google Scholar] [CrossRef] [PubMed]
- Malaviya, R.; Morrison, A.R.; Pentland, A.P. Histamine in human epidermal cells is induced by ultraviolet light injury. J. Investig. Dermatol. 1996, 106, 785–789. [Google Scholar] [CrossRef] [PubMed]
- Thomas, C.M.; Hong, T.; van Pijkeren, J.P.; Hemarajata, P.; Trinh, D.V.; Hu, W.; Britton, R.A.; Kalkum, M.; Versalovic, J. Histamine derived from probiotic Lactobacillus reuteri suppresses TNF via modulation of PKA and ERK signaling. PLoS ONE 2012, 7, e31951. [Google Scholar] [CrossRef]
- Ferstl, R.; Frei, R.; Schiavi, E.; Konieczna, P.; Barcik, W.; Ziegler, M.; Lauener, R.P.; Chassard, C.; Lacroix, C.; Akdis, C.A.; et al. Histamine receptor 2 is a key influence in immune responses to intestinal histamine-secreting microbes. J. Allergy Clin. Immunol. 2014, 134, 744–746. [Google Scholar] [CrossRef] [PubMed]
- Penders, J.; Stobberingh, E.E.; van den Brandt, P.A.; Thijs, C. The role of the intestinal microbiota in the development of atopic disorders. Allergy 2007, 62, 1223–1236. [Google Scholar] [CrossRef] [PubMed]
- Nakamizo, S.; Egawa, G.; Honda, T.; Nakajima, S.; Belkaid, Y.; Kabashima, K. Commensal bacteria and cutaneous immunity. Semin. Immunopathol. 2015, 37, 73–80. [Google Scholar] [CrossRef] [PubMed]
- Sanford, J.A.; Gallo, R.L. Functions of the skin microbiota in health and disease. Semin. Immunol. 2013, 25, 370–377. [Google Scholar] [CrossRef] [PubMed]
- Gutowska-Owsiak, D.; Greenwald, L.; Watson, C.; Selvakumar, T.A.; Wang, X.; Ogg, G.S. The histamine-synthesizing enzyme histidine decarboxylase is upregulated by keratinocytes in atopic skin. Br. J. Dermatol. 2014, 171, 771–778. [Google Scholar] [CrossRef] [PubMed]
- Simons, F.E.; Simons, K.J. The pharmacology and use of H1-receptor-antagonist drugs. N. Engl. J. Med. 1994, 330, 1663–1670. [Google Scholar] [CrossRef] [PubMed]
- Gutzmer, R.; Gschwandtner, M.; Rossbach, K.; Mommert, S.; Werfel, T.; Kietzmann, M.; Baeumer, W. Pathogenetic and therapeutic implications of the histamine H4 receptor in inflammatory skin diseases and pruritus. Front. Biosci. (Schol. Ed.) 2011, 3, 985–994. [Google Scholar] [CrossRef]
- Chimalakonda, K.C.; Pang, E.; Weaver, J.L.; Howard, K.E.; Patel, V.; Boyne, M.T., 2nd. Development and validation of a liquid-chromatography tandem mass spectrometry method to determine in vitro and in vivo histamine release. J. Pharm. Biomed. Anal. 2014, 102, 494–499. [Google Scholar] [CrossRef] [PubMed]
- Ash, A.S.; Schild, H.O. Receptors mediating some actions of histamine. Br. J. Pharmacol. Chemother. 1966, 27, 427–439. [Google Scholar] [CrossRef] [PubMed]
- Lovenberg, T.W.; Roland, B.L.; Wilson, S.J.; Jiang, X.; Pyati, J.; Huvar, A.; Jackson, M.R.; Erlander, M.G. Cloning and functional expression of the human histamine H3 receptor. Mol. Pharmacol. 1999, 55, 1101–1107. [Google Scholar] [PubMed]
- Oda, T.; Morikawa, N.; Saito, Y.; Masuho, Y.; Matsumoto, S. Molecular cloning and characterization of a novel type of histamine receptor preferentially expressed in leukocytes. J. Biol. Chem. 2000, 275, 36781–36786. [Google Scholar] [CrossRef] [PubMed]
- Arrang, J.M.; Garbarg, M.; Schwartz, J.C. Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature 1983, 302, 832–837. [Google Scholar] [CrossRef] [PubMed]
- O’Mahony, L.; Akdis, M.; Akdis, C.A. Regulation of the immune response and inflammation by histamine and histamine receptors. J. Allergy Clin. Immunol. 2011, 128, 1153–1162. [Google Scholar] [CrossRef] [PubMed]
- Sander, L.E.; Lorentz, A.; Sellge, G.; Coeffier, M.; Neipp, M.; Veres, T.; Frieling, T.; Meier, P.N.; Manns, M.P.; Bischoff, S.C. Selective expression of histamine receptors H1R, H2R, and H4R, but not H3R, in the human intestinal tract. Gut 2006, 55, 498–504. [Google Scholar] [CrossRef] [PubMed]
- Mommert, S.; Gschwandtner, M.; Koether, B.; Gutzmer, R.; Werfel, T. Human memory Th17 cells express a functional histamine H4 receptor. Am. J. Pathol. 2012, 180, 177–185. [Google Scholar] [CrossRef] [PubMed]
- Baumer, W.; Wendorff, S.; Gutzmer, R.; Werfel, T.; Dijkstra, D.; Chazot, P.; Stark, H.; Kietzmann, M. Histamine H4 receptors modulate dendritic cell migration through skin—Immunomodulatory role of histamine. Allergy 2008, 63, 1387–1394. [Google Scholar] [CrossRef] [PubMed]
- Dunford, P.J.; O’Donnell, N.; Riley, J.P.; Williams, K.N.; Karlsson, L.; Thurmond, R.L. The histamine H4 receptor mediates allergic airway inflammation by regulating the activation of CD4+ T cells. J. Immunol. 2006, 176, 7062–7070. [Google Scholar] [PubMed]
- Jemima, E.A.; Prema, A.; Thangam, E.B. Functional characterization of histamine H4 receptor on human mast cells. Mol. Immunol. 2014, 62, 19–28. [Google Scholar] [CrossRef] [PubMed]
- O’Reilly, M.; Alpert, R.; Jenkinson, S.; Gladue, R.P.; Foo, S.; Trim, S.; Peter, B.; Trevethick, M.; Fidock, M. Identification of a histamine H4 receptor on human eosinophils—Role in eosinophil chemotaxis. J. Recept. Signal Transduct. Res. 2002, 22, 431–448. [Google Scholar] [CrossRef] [PubMed]
- Gschwandtner, M.; Rossbach, K.; Dijkstra, D.; Baumer, W.; Kietzmann, M.; Stark, H.; Werfel, T.; Gutzmer, R. Murine and human Langerhans cells express a functional histamine H4 receptor: Modulation of cell migration and function. Allergy 2010, 65, 840–849. [Google Scholar] [CrossRef] [PubMed]
- Ohtani, T.; Aiba, S.; Mizuashi, M.; Mollah, Z.U.; Nakagawa, S.; Tagami, H. H1 and H2 histamine receptors are absent on Langerhans cells and present on dermal dendritic cells. J. Investig. Dermatol 2003, 121, 1073–1079. [Google Scholar] [CrossRef] [PubMed]
- Glatzer, F.; Gschwandtner, M.; Ehling, S.; Rossbach, K.; Janik, K.; Klos, A.; Baumer, W.; Kietzmann, M.; Werfel, T.; Gutzmer, R. Histamine induces proliferation in keratinocytes from patients with atopic dermatitis through the histamine 4 receptor. J. Allergy Clin. Immunol. 2013, 132, 1358–1367. [Google Scholar] [CrossRef] [PubMed]
- MacGlashan, D., Jr. Histamine: A mediator of inflammation. J. Allergy Clin. Immunol. 2003, 112, S53–S59. [Google Scholar] [CrossRef] [PubMed]
- Jutel, M.; Akdis, M.; Akdis, C.A. Histamine, histamine receptors and their role in immune pathology. Clin. Exp. Allergy 2009, 39, 1786–1800. [Google Scholar] [CrossRef] [PubMed]
- Akdis, C.A.; Simons, F.E. Histamine receptors are hot in immunopharmacology. Eur. J. Pharmacol. 2006, 533, 69–76. [Google Scholar] [CrossRef] [PubMed]
- Lim, H.D.; van Rijn, R.M.; Ling, P.; Bakker, R.A.; Thurmond, R.L.; Leurs, R. Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: Identification of 4-methylhistamine as the first potent and selective H4 receptor agonist. J. Pharmacol. Exp. Ther. 2005, 314, 1310–1321. [Google Scholar] [CrossRef] [PubMed]
- Leurs, R.; Chazot, P.L.; Shenton, F.C.; Lim, H.D.; de Esch, I.J. Molecular and biochemical pharmacology of the histamine H4 receptor. Br. J. Pharmacol. 2009, 157, 14–23. [Google Scholar] [CrossRef] [PubMed]
- Morse, K.L.; Behan, J.; Laz, T.M.; West, R.E., Jr.; Greenfeder, S.A.; Anthes, J.C.; Umland, S.; Wan, Y.; Hipkin, R.W.; Gonsiorek, W.; et al. Cloning and characterization of a novel human histamine receptor. J. Pharmacol. Exp. Ther. 2001, 296, 1058–1066. [Google Scholar] [PubMed]
- Horr, B.; Borck, H.; Thurmond, R.; Grosch, S.; Diel, F. STAT1 phosphorylation and cleavage is regulated by the histamine (H4) receptor in human atopic and non-atopic lymphocytes. Int. Immunopharmacol. 2006, 6, 1577–1585. [Google Scholar] [CrossRef] [PubMed]
- Michel, I.; Borck, H.; McElligott, S.; Krieg, C.; Diel, F. Histamine receptor H4R-selective ligands influence the STAT6 transcription activation domain (TAD) and the DNA-binding. Inflamm. Res. 2008, 57, S47–S48. [Google Scholar] [CrossRef] [PubMed]
- Kuhne, S.; Wijtmans, M.; Lim, H.D.; Leurs, R.; de Esch, I.J. Several down, a few to go: Histamine H3 receptor ligands making the final push towards the market? Expert Opin. Investig. Drugs 2011, 20, 1629–1648. [Google Scholar] [CrossRef]
- Kiss, R.; Keseru, G.M. Novel histamine H4 receptor ligands and their potential therapeutic applications: An update. Expert Opin. Ther. Pat. 2014, 24, 1185–1197. [Google Scholar] [CrossRef]
- Van der Pol, R.; Langendam, M.; Benninga, M.; van Wijk, M.; Tabbers, M. Efficacy and safety of histamine-2 receptor antagonists. JAMA Pediatri. 2014, 168, 947–954. [Google Scholar] [CrossRef]
- Simons, F.E.; Simons, K.J. H1 antihistamines: Current status and future directions. World Allergy Organ. J. 2008, 1, 145–155. [Google Scholar] [CrossRef] [PubMed]
- Bielory, L.; Ghafoor, S. Histamine receptors and the conjunctiva. Curr. Opin. Allergy Clin. Immunol. 2005, 5, 437–440. [Google Scholar] [CrossRef] [PubMed]
- Amano, T.; Takeda, T.; Yano, H.; Tamura, T. Olopatadine hydrochloride accelerates the recovery of skin barrier function in mice. Br. J. Dermatol. 2007, 156, 906–912. [Google Scholar] [CrossRef] [PubMed]
- Higashi, M.; Ohsawa, I.; Oda, F.; Yamada, Y.; Kawana, S.; Iida, K.; Mitsuishi, T. Histamine H1-receptor antagonistic drug olopatadine suppresses TSLP in atopic dermatitis model mice. Allergol. Int. 2013, 62, 137–138. [Google Scholar] [CrossRef] [PubMed]
- Ito, T.; Fujiyama, T.; Hashizume, H.; Tokura, Y. Antihistaminic drug olopatadine downmodulates T cell chemotaxis toward CXCL10 by reducing CXCR3 expression, F-actin polymerization and calcium influx in patients with alopecia areata. J. Dermatol. Sci. 2013, 72, 68–71. [Google Scholar] [CrossRef] [PubMed]
- Murota, H.; El-latif, M.A.; Tamura, T.; Katayama, I. Olopatadine hydrochloride decreases tissue interleukin-31 levels in an atopic dermatitis mouse model. Acta Derm. Venereol. 2014, 94, 78–79. [Google Scholar] [CrossRef] [PubMed]
- Tamura, T.; Matsubara, M.; Amano, T.; Chida, M. Olopatadine ameliorates rat experimental cutaneous inflammation by improving skin barrier function. Pharmacology 2008, 81, 118–126. [Google Scholar] [CrossRef] [PubMed]
- Ohmori, K.; Hayashi, K.; Kaise, T.; Ohshima, E.; Kobayashi, S.; Yamazaki, T.; Mukouyama, A. Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug. Jpn. J. Pharmacol. 2002, 88, 379–397. [Google Scholar] [CrossRef]
- Hofstra, C.L.; Desai, P.J.; Thurmond, R.L.; Fung-Leung, W.P. Histamine H4 receptor mediates chemotaxis and calcium mobilization of mast cells. J. Pharmacol. Exp. Ther. 2003, 305, 1212–1221. [Google Scholar] [CrossRef] [PubMed]
- Morgan, R.K.; McAllister, B.; Cross, L.; Green, D.S.; Kornfeld, H.; Center, D.M.; Cruikshank, W.W. Histamine 4 receptor activation induces recruitment of FOXP3+ T cells and inhibits allergic asthma in a murine model. J. Immunol. 2007, 178, 8081–8089. [Google Scholar] [CrossRef] [PubMed]
- Gutzmer, R.; Diestel, C.; Mommert, S.; Kother, B.; Stark, H.; Wittmann, M.; Werfel, T. Histamine H4 receptor stimulation suppresses IL-12p70 production and mediates chemotaxis in human monocyte-derived dendritic cells. J. Immunol. 2005, 174, 5224–5232. [Google Scholar] [CrossRef] [PubMed]
- Dijkstra, D.; Leurs, R.; Chazot, P.; Shenton, F.C.; Stark, H.; Werfel, T.; Gutzmer, R. Histamine downregulates monocyte CCL2 production through the histamine H4 receptor. J. Allergy Clin. Immunol. 2007, 120, 300–307. [Google Scholar] [CrossRef] [PubMed]
- Thurmond, R.L.; Gelfand, E.W.; Dunford, P.J. The role of histamine H1 and H4 receptors in allergic inflammation: The search for new antihistamines. Nat. Rev. Drug Discov. 2008, 7, 41–53. [Google Scholar] [CrossRef] [PubMed]
- Ohsawa, Y.; Hirasawa, N. The role of histamine H1 and H4 receptors in atopic dermatitis: From basic research to clinical study. Allergol. Int. 2014, 63, 533–542. [Google Scholar] [CrossRef] [PubMed]
- Murata, Y.; Song, M.; Kikuchi, H.; Hisamichi, K.; Xu, X.L.; Greenspan, A.; Kato, M.; Chiou, C.F.; Kato, T.; Guzzo, C.; et al. Phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of a H4 R-antagonist (JNJ-39758979) in Japanese adults with moderate atopic dermatitis. J. Dermatol. 2014, 42, 129–139. [Google Scholar] [CrossRef] [PubMed]
- Gschwandtner, M.; Mildner, M.; Mlitz, V.; Gruber, F.; Eckhart, L.; Werfel, T.; Gutzmer, R.; Elias, P.M.; Tschachler, E. Histamine suppresses epidermal keratinocyte differentiation and impairs skin barrier function in a human skin model. Allergy 2013, 68, 37–47. [Google Scholar] [CrossRef] [PubMed]
- Tamura, T.; Komai, M. Effect of olopatadine hydrochloride, an anti-histamine drug, on rhinitis induced by intranasal instillation of toluene-2,4-diisocyanate in rats. Int. Immunopharmacol. 2008, 8, 916–921. [Google Scholar] [CrossRef] [PubMed]
- Ashida, Y.; Denda, M.; Hirao, T. Histamine H1 and H2 receptor antagonists accelerate skin barrier repair and prevent epidermal hyperplasia induced by barrier disruption in a dry environment. J. Investig. Dermatol. 2001, 116, 261–265. [Google Scholar] [CrossRef] [PubMed]
- Lin, T.K.; Man, M.Q.; Santiago, J.L.; Park, K.; Roelandt, T.; Oda, Y.; Hupe, M.; Crumrine, D.; Lee, H.J.; Gschwandtner, M.; et al. Topical antihistamines display potent anti-inflammatory activity linked in part to enhanced permeability barrier function. J. Investig. Dermatol. 2013, 133, 469–478. [Google Scholar] [CrossRef] [PubMed]
- Zabner, J.; Winter, M.; Excoffon, K.J.; Stoltz, D.; Ries, D.; Shasby, S.; Shasby, M. Histamine alters E-cadherin cell adhesion to increase human airway epithelial permeability. J. Appl. Physiol. 2003, 95, 394–401. [Google Scholar] [PubMed]
- Srinivas, S.P.; Satpathy, M.; Guo, Y.; Anandan, V. Histamine-induced phosphorylation of the regulatory light chain of myosin II disrupts the barrier integrity of corneal endothelial cells. Investig. Ophthalmol. Vis. Sci. 2006, 47, 4011–4018. [Google Scholar] [CrossRef]
- Takeuchi, K.; Kishioka, C.; Ishinaga, H.; Sakakura, Y.; Majima, Y. Histamine alters gene expression in cultured human nasal epithelial cells. J. Allergy Clin. Immunol. 2001, 107, 310–314. [Google Scholar] [CrossRef] [PubMed]
- Kuo, I.H.; Carpenter-Mendini, A.; Yoshida, T.; McGirt, L.Y.; Ivanov, A.I.; Barnes, K.C.; Gallo, R.L.; Borkowski, A.W.; Yamasaki, K.; Leung, D.Y.; et al. Activation of epidermal toll-like receptor 2 enhances tight junction function: Implications for atopic dermatitis and skin barrier repair. J. Investig. Dermatol. 2013, 133, 988–998. [Google Scholar] [CrossRef] [PubMed]
- Kanda, N.; Watanabe, S. Histamine enhances the production of human beta-defensin-2 in human keratinocytes. Am. J. Physiol. Cell Physiol. 2007, 293, C1916–C1923. [Google Scholar] [CrossRef] [PubMed]
- Niyonsaba, F.; Ushio, H.; Nakano, N.; Ng, W.; Sayama, K.; Hashimoto, K.; Nagaoka, I.; Okumura, K.; Ogawa, H. Antimicrobial peptides human beta-defensins stimulate epidermal keratinocyte migration, proliferation and production of proinflammatory cytokines and chemokines. J. Investig. Dermatol. 2007, 127, 594–604. [Google Scholar] [CrossRef] [PubMed]
- Danso, M.O.; van Drongelen, V.; Mulder, A.; van Esch, J.; Scott, H.; van Smeden, J.; El Ghalbzouri, A.; Bouwstra, J.A. TNF-alpha and Th2 cytokines induce atopic dermatitis-like features on epidermal differentiation proteins and stratum corneum lipids in human skin equivalents. J. Investig. Dermatol. 2014, 134, 1941–1950. [Google Scholar] [CrossRef] [PubMed]
- Howell, M.D.; Kim, B.E.; Gao, P.; Grant, A.V.; Boguniewicz, M.; Debenedetto, A.; Schneider, L.; Beck, L.A.; Barnes, K.C.; Leung, D.Y. Cytokine modulation of atopic dermatitis filaggrin skin expression. J. Allergy Clin. Immunol. 2007, 120, 150–155. [Google Scholar] [CrossRef] [PubMed]
- Gutowska-Owsiak, D.; Schaupp, A.L.; Salimi, M.; Taylor, S.; Ogg, G.S. Interleukin-22 downregulates filaggrin expression and affects expression of profilaggrin processing enzymes. Br. J. Dermatol. 2011, 165, 492–498. [Google Scholar] [CrossRef] [PubMed]
- Thyssen, J.P.; Kezic, S. Causes of epidermal filaggrin reduction and their role in the pathogenesis of atopic dermatitis. J. Allergy Clin. Immunol. 2014, 134, 792–799. [Google Scholar] [CrossRef] [PubMed]
© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
De Benedetto, A.; Yoshida, T.; Fridy, S.; Park, J.-E.S.; Kuo, I.-H.; Beck, L.A. Histamine and Skin Barrier: Are Histamine Antagonists Useful for the Prevention or Treatment of Atopic Dermatitis? J. Clin. Med. 2015, 4, 741-755. https://doi.org/10.3390/jcm4040741
De Benedetto A, Yoshida T, Fridy S, Park J-ES, Kuo I-H, Beck LA. Histamine and Skin Barrier: Are Histamine Antagonists Useful for the Prevention or Treatment of Atopic Dermatitis? Journal of Clinical Medicine. 2015; 4(4):741-755. https://doi.org/10.3390/jcm4040741
Chicago/Turabian StyleDe Benedetto, Anna, Takeshi Yoshida, Sade Fridy, Joo-Eun S. Park, I.-Hsin Kuo, and Lisa A. Beck. 2015. "Histamine and Skin Barrier: Are Histamine Antagonists Useful for the Prevention or Treatment of Atopic Dermatitis?" Journal of Clinical Medicine 4, no. 4: 741-755. https://doi.org/10.3390/jcm4040741